Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

NCT06704724 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06704724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06704724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
December 10, 2024
Completion date
May 12, 2026
Enrollment
30 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, pancreatic ductal, colorectal neoplasms